{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-122353","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.591654+00:00","generated_at":"2026-05-16T12:46:35.751500+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gain Therapeutics reports positive exploratory endpoint from Phase 1b study of GT-02287 in Parkinson's Disease","bullets":["GT-02287 reduced elevated GluSph in CSF to near-normal levels after 90 days in Phase 1b study.","19 of 21 enrolled participants completed 90-day dosing; 15 (79%) chose to continue in 9-month extension ending Sept 2026.","Drug well-tolerated; data monitoring committee recommended study continue with no changes.","Company has capital to fund operations through end of Phase 1b extension and year-end 2026.","Phase 1 healthy volunteer study showed favorable safety, target engagement with increased GCase activity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-122353","json":"https://secwatch.observer/filing/0001104659-25-122353.json","markdown":"https://secwatch.observer/filing/0001104659-25-122353.md","text":"https://secwatch.observer/filing/0001104659-25-122353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925122353/0001104659-25-122353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925122353/tm2533810d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:46:35.751500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}